{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:57:44Z","timestamp":1774072664087,"version":"3.50.1"},"reference-count":43,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chinese University of Hong Kong (CUHK) Impact Research Scheme","award":["3133072"],"award-info":[{"award-number":["3133072"]}]},{"name":"Chinese University of Hong Kong (CUHK) Impact Research Scheme","award":["MS200084_0031"],"award-info":[{"award-number":["MS200084_0031"]}]},{"name":"Asia Diabetes Foundation","award":["3133072"],"award-info":[{"award-number":["3133072"]}]},{"name":"Asia Diabetes Foundation","award":["MS200084_0031"],"award-info":[{"award-number":["MS200084_0031"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Type 2 diabetes (T2D)-associated end-stage kidney disease (ESKD) is a global burden, while the renoprotective effects of metformin remain controversial. In a population-based cohort (2002\u20132018) including 96,643 patients with T2D observed for 0.7 million person-years, we estimated the risk association of metformin and its dose-relationship with ESKD in a propensity-score overlap-weighting (PS-OW) cohort by eGFR categories. Amongst 96,643, 83,881 (86.8%) had eGFR-G1\/G2 (\u226560 mL\/min\/1.73 m2), 8762 (9.1%) had eGFR-G3a (\u226545\u201360 mL\/min\/1.73 m2), 3051 (3.2%) had eGFR-G3b (\u226530\u201345 mL\/min\/1.73 m2), and 949 (1.0%) had eGFR-G4 (\u226515\u201330 mL\/min\/1.73 m2). The respective proportions of metformin users in these eGFR categories were 95.1%, 81.9%, 53.8%, and 20.8%. In the PS-OW cohort with 88,771 new-metformin and 7872 other oral glucose-lowering-drugs (OGLDs) users, the respective incidence rates of ESKD were 2.8 versus 22.4\/1000 person-years. Metformin use associated with reduced risk of ESKD (hazard ratio (HR) = 0.43 [95% CI: 0.35\u20130.52] in eGFR-G1\/G2, 0.64 [0.52\u20130.79] in eGFR-G3a, 0.67 [0.56\u20130.80] in eGFR-G3b, and 0.63 [0.48\u20130.83] in eGFR-G4). Metformin use was associated with reduced or neutral risk of major adverse cardiovascular events (MACE) (7.2 versus 16.0\/1000 person-years) and all-cause mortality (14.6 versus 65.1\/1000 person-years). Time-weighted mean daily metformin dose was 1000 mg in eGFR-G1\/G2, 850 mg in eGFR-G3a, 650 mg in eGFR-G3b, and 500 mg in eGFR-G4. In a subcohort of 14,766 patients observed for 0.1 million person-years, the respective incidence rates of lactic acidosis and HR in metformin users and non-users were 42.5 versus 226.4 events\/100,000 person-years (p = 0.03) for eGFR-G1\/G2 (HR = 0.57, 0.25\u20131.30) and 54.5 versus 300.6 events\/100,000 person-years (p = 0.01) for eGFR-G3\/G4 (HR = 0.49, 0.19\u20131.30). These real-world data underscore the major benefits and low risk of lactic acidosis with metformin use down to an eGFR of 30 mL\/min\/1.73 m2 and possibly even 15 mL\/min\/1.73 m2, while reinforcing the importance of dose adjustment and frequent monitoring of eGFR.<\/jats:p>","DOI":"10.3390\/ph15091140","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T22:37:28Z","timestamp":1663108648000},"page":"1140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Attenuated Risk Association of End-Stage Kidney Disease with Metformin in Type 2 Diabetes with eGFR Categories 1\u20134"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2968-1762","authenticated-orcid":false,"given":"Aimin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S. H.","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Asia Diabetes Foundation, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1227-803X","authenticated-orcid":false,"given":"Ronald C. W.","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice P. S.","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing Yee","family":"So","sequence":"additional","affiliation":[{"name":"Hong Kong Hospital Authority Head Office, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea O. Y.","family":"Luk","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy W. C.","family":"Fu","sequence":"additional","affiliation":[{"name":"Asia Diabetes Foundation, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-1194","authenticated-orcid":false,"given":"Juliana C. N.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Asia Diabetes Foundation, Hong Kong SAR 999077, China"},{"name":"Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Chow","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"},{"name":"Phase 1 Clinical Trial Centre, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: Historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"Inzucchi, S.E. (2021, August 03). FDA Drug Safety Communication: FDA Revises Warnings Regarding Use of the Diabetes Medicine Metformin in Certain Patients with Reduced Kidney Function, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chow, E., Yang, A., Chung, C.H.L., and Chan, J.C.N. (2022). A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer. Pharmaceuticals, 15.","DOI":"10.3390\/ph15040442"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00125-021-05452-0","article-title":"Long-term metformin use and risk of pneumonia and related death in type 2 diabetes: A registry-based cohort study","volume":"64","author":"Yang","year":"2021","journal-title":"Diabetologia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1097\/TP.0000000000002864","article-title":"Metformin Attenuates Cyclosporine A-induced Renal Fibrosis in Rats","volume":"103","author":"Lin","year":"2019","journal-title":"Transplantation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"F727","DOI":"10.1152\/ajprenal.00293.2013","article-title":"Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease","volume":"305","author":"Satriano","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: A systematic review and an updated meta-analysis","volume":"18","author":"Han","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2337\/dc19-0936","article-title":"The Long-term Effects of Metformin on Patients with Type 2 Diabetic Kidney Disease","volume":"43","author":"Kwon","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.2337\/dc20-1591","article-title":"Comment on Kwon et al. The Long-term Effects of Metformin on Patients with Type 2 Diabetic Kidney Disease","volume":"43","author":"Fu","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"559446","DOI":"10.3389\/fendo.2020.559446","article-title":"Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients with Chronic Kidney Disease\u2014A Systematic Review and Meta-Analysis","volume":"11","author":"Hu","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.13642","article-title":"Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease","volume":"21","author":"Charytan","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(15)00123-0","article-title":"Metformin use and mortality in patients with advanced chronic kidney disease: National, retrospective, observational, cohort study","volume":"3","author":"Hung","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mayocp.2019.07.017","article-title":"A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study","volume":"95","author":"Whitlock","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/M20-5938","article-title":"Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline","volume":"174","author":"Navaneethan","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.diabres.2008.09.033","article-title":"Diabetic nephropathy\u2014What are the unmet needs?","volume":"82","author":"Luk","year":"2008","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.kint.2020.04.059","article-title":"Does metformin do more benefit or harm in chronic kidney disease patients?","volume":"98","author":"Jouret","year":"2020","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/dme.13014","article-title":"Quality of care in patients with diabetic kidney disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry","volume":"33","author":"Luk","year":"2016","journal-title":"Diabet. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Manski-Nankervis, J.A., Thuraisingam, S., Sluggett, J.K., Kilov, G., Furler, J., O\u2019Neal, D., and Jenkins, A. (2019). Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: A national cross-sectional study. BMC Fam. Pract., 20.","DOI":"10.1186\/s12875-019-0915-x"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Busch, M., Nadal, J., Schmid, M., Paul, K., Titze, S., H\u00fcbner, S., K\u00f6ttgen, A., Schultheiss, U.T., Baid-Agrawal, S., and Lorenzen, J. (2016). Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease\u2014Cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrol., 17.","DOI":"10.1186\/s12882-016-0273-z"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2180373","DOI":"10.1155\/2018\/2180373","article-title":"Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome","volume":"2018","author":"Mihai","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/dc19-2391","article-title":"Hospitalization for Lactic Acidosis Among Patients with Reduced Kidney Function Treated with Metformin or Sulfonylureas","volume":"43","author":"Chu","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2018.0292","article-title":"Association of Metformin Use with Risk of Lactic Acidosis Across the Range of Kidney Function","volume":"178","author":"Lazarus","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2337\/dc17-2231","article-title":"Metformin Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4","volume":"41","author":"Lalau","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/jama.2019.21558","article-title":"Using Propensity Score Methods to Create Target Populations in Observational Clinical Research","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s00125-020-05217-1","article-title":"Real-world evidence: The devil is in the detail","volume":"63","author":"Gokhale","year":"2020","journal-title":"Diabetologia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1111\/dom.12974","article-title":"Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm","volume":"19","author":"Lalau","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.2337\/dci19-0003","article-title":"From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions","volume":"42","author":"Chan","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/ije\/dyab252","article-title":"Data Resource Profile: The Hong Kong Diabetes Surveillance Database (HKDSD)","volume":"51","author":"Wu","year":"2021","journal-title":"Int. J. Epidemiol."},{"key":"ref_32","first-page":"100509","article-title":"Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-Year trends in 0\u00b7 9 million adults with Diabetes in Hong Kong (2002\u20132019)","volume":"26","author":"Yang","year":"2022","journal-title":"Lancet Reg. Health-West. Pac."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"109233","DOI":"10.1016\/j.diabres.2022.109233","article-title":"Time-varying risk associations of renin angiotensin system inhibitors with pneumonia and related deaths in a cohort of 252,616 patients with diabetes (2002\u20132019)","volume":"185","author":"Yang","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/endrev\/bnab007","article-title":"Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments","volume":"42","author":"Schneeweiss","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/80.4.484","article-title":"Definition of Clinically Relevant Lactic Acidosis in Patients with Internal Diseases","volume":"80","author":"Luft","year":"1983","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/dc20-0260","article-title":"Trends in glucose-lowering drug use, glycemic control, and severe hypoglycemia in adults with diabetes in Hong Kong, 2002\u20132016","volume":"43","author":"Yang","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pds.2074","article-title":"The role of the c-statistic in variable selection for propensity score models","volume":"20","author":"Westreich","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why Test for Proportional Hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1177\/0962280219881168","article-title":"Imputing missing time-dependent covariate values for the discrete time Cox model","volume":"29","author":"Murad","year":"2020","journal-title":"Stat. Methods Med. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","article-title":"Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment","volume":"98","author":"Caramori","year":"2020","journal-title":"Kidney Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/9\/1140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:30:18Z","timestamp":1760142618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/9\/1140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ph15091140"],"URL":"https:\/\/doi.org\/10.3390\/ph15091140","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}